GM Advisory Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

GM Advisory Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,550	Closed	-$243K	–	129
2018 Q2	$243K	Hold	2,550	–	–	0.07%	99
2018 Q1	$224K	Hold	2,550	–	–	0.07%	112
2017 Q4	$216K	Hold	2,550	–	–	0.06%	120
2017 Q3	$221K	Buy	+2,550	New	+$204K	0.07%	107

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

GM Advisory Group's XBI Position: Q3 2018 in Review

GM Advisory Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2018, closing a stake of 2,550 shares — an estimated $243K sold.

GM Advisory Group first reported a position in XBI in Q3 2017 and held it in 4 quarters. The position peaked at $243K in Q2 2018. 432 funds tracked by Wall St. Rank hold XBI as of Q3 2018.

GM Advisory Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2018 after selling out during the quarter.
GM Advisory Group sold 2,550 State Street SPDR S&P Biotech ETF shares in Q3 2018, an estimated $243K.
GM Advisory Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and held it in 4 quarters.
GM Advisory Group's State Street SPDR S&P Biotech ETF position peaked at $243K in Q2 2018.
432 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2018.

Based on GM Advisory Group's 13F filing for Q3 2018, filed 13 Nov 2018.